Trademark Overview
On Tuesday, June 25, 2024, a trademark application was filed for LANJEDA with the United States Patent and Trademark Office. The USPTO has given the LANJEDA trademark a serial number of 98617112. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, June 25, 2024. This trademark is owned by Glaxo Group Limited. The LANJEDA trademark is filed in the Pharmaceutical Products category with the following description:
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders